R.H. Bluestein & Co’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $1.01M | Sell |
20,200
-1,800
| -8% | -$96.4K | 0.06% | 90 |
|
|
2022
Q2 | $1.23M | Sell |
22,000
-14,000
| -39% | -$777K | 0.08% | 83 |
|
|
2022
Q1 | $2M | Buy |
36,000
+1,600
| +5% | +$82.1K | 0.08% | 69 |
|
|
2021
Q4 | $1.93M | Sell |
34,400
-8,000
| -19% | -$433K | 0.07% | 65 |
|
|
2021
Q3 | $2.04M | Hold |
42,400
| – | – | 0.08% | 66 |
|
|
2021
Q2 | $1.78M | Buy |
42,400
+1,400
| +3% | +$54.3K | 0.07% | 78 |
|
|
2021
Q1 | $1.38M | Buy |
41,000
+21,000
| +105% | +$748K | 0.06% | 82 |
|
|
2020
Q4 | $699K | Sell |
20,000
-10,000
| -33% | -$346K | 0.03% | 139 |
|
|
2020
Q3 | $1.04M | Hold |
30,000
| – | – | 0.05% | 91 |
|
|
2020
Q2 | $982K | Hold |
30,000
| – | – | 0.06% | 95 |
|
|
2020
Q1 | $903K | Hold |
30,000
| – | – | 0.08% | 81 |
|
|
2019
Q4 | $868K | Hold |
30,000
| – | – | 0.04% | 92 |
|
|
2019
Q3 | $776K | Sell |
30,000
-6,000
| -17% | -$152K | 0.04% | 94 |
|
|
2019
Q2 | $919K | Hold |
36,000
| – | – | 0.05% | 75 |
|
|
2019
Q1 | $942K | Hold |
36,000
| – | – | 0.05% | 73 |
|
|
2018
Q4 | $829K | Sell |
36,000
-4,000
| -10% | -$88.9K | 0.06% | 64 |
|
|
2018
Q3 | $943K | Hold |
40,000
| – | – | 0.05% | 88 |
|
|
2018
Q2 | $922K | Hold |
40,000
| – | – | 0.05% | 81 |
|
|
2018
Q1 | $985K | Hold |
40,000
| – | – | 0.05% | 90 |
|
|
2017
Q4 | $1.07M | Hold |
40,000
| – | – | 0.06% | 76 |
|
|
2017
Q3 | $963K | Hold |
40,000
| – | – | 0.05% | 90 |
|
|
2017
Q2 | $858K | Hold |
40,000
| – | – | 0.05% | 86 |
|
|
2017
Q1 | $686K | Hold |
40,000
| – | – | 0.04% | 105 |
|
|
2016
Q4 | $717K | Sell |
40,000
-38
| -0.1% | -$689 | 0.05% | 97 |
|
|
2016
Q3 | $833K | Buy |
40,038
+38
| +0.1% | +$942 | 0.05% | 77 |
|
|
2016
Q2 | $1.08M | Sell |
40,000
-10,000
| -20% | -$274K | 0.08% | 50 |
|
|
2016
Q1 | $1.35M | Hold |
50,000
| – | – | 0.1% | 56 |
|
|
2015
Q4 | $1.45M | Sell |
50,000
-50
| -0.1% | -$1.38K | 0.09% | 59 |
|
|
2015
Q3 | $1.36M | Sell |
50,050
-4,000
| -7% | -$113K | 0.1% | 64 |
|
|
2015
Q2 | $1.48M | Sell |
54,050
-6,000
| -10% | -$169K | 0.09% | 67 |
|
|
2015
Q1 | $1.6M | Hold |
60,050
| – | – | 0.1% | 66 |
|
|
2014
Q4 | $1.27M | Hold |
60,050
| – | – | 0.08% | 88 |
|
|
2014
Q3 | $1.43M | Hold |
60,050
| – | – | 0.09% | 82 |
|
|
2014
Q2 | $1.39M | Sell |
60,050
-500
| -0.8% | -$11K | 0.08% | 84 |
|
|
2014
Q1 | $1.38M | Sell |
60,550
-23,000
| -28% | -$490K | 0.09% | 83 |
|
|
2013
Q4 | $1.54M | Hold |
83,550
| – | – | 0.1% | 77 |
|
|
2013
Q3 | $1.41M | Buy |
83,550
+150
| +0.2% | +$2.52K | 0.1% | 81 |
|
|
2013
Q2 | $1.29M | Buy |
+83,400
| New | +$1.39M | 0.11% | 78 |
|
Other funds holding NVO
F
R.H. Bluestein & Co's NVO Position: Q3 2022 in Review
R.H. Bluestein & Co reduced its Novo Nordisk (NVO) stake by 8.2% in Q3 2022, selling an estimated $96.4K and leaving 20,200 shares worth $1.01M. The position accounts for 0.06% of the portfolio, ranked #90.
R.H. Bluestein & Co first reported a position in NVO in Q2 2013 and has held it in 38 quarters since. The position peaked at $2.04M in Q3 2021. 907 funds tracked by Wall St. Rank hold NVO as of Q3 2022.
- R.H. Bluestein & Co held 20,200 shares of Novo Nordisk worth $1.01M as of Q3 2022.
- R.H. Bluestein & Co sold 1,800 Novo Nordisk shares in Q3 2022, an estimated $96.4K.
- Novo Nordisk made up 0.06% of R.H. Bluestein & Co's portfolio in Q3 2022, its #90 holding.
- R.H. Bluestein & Co first reported a position in Novo Nordisk in Q2 2013 and has held it in 38 quarters since.
- R.H. Bluestein & Co's Novo Nordisk position peaked at $2.04M in Q3 2021.
- 907 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2022.
Based on R.H. Bluestein & Co's 13F filing for Q3 2022, filed 14 Nov 2022.